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Background and aim: Kawasaki disease (KD) is an acute febrile, self-limiting, and
systemic vasculitis of unknown etiology. MEFV gene has a major role in autoinﬂammatory
disorders and innate immune reactions. Several reports revealed that MEFV gene mutations
are associated with systemic vasculitis. The aim of this study was to determine the associa-
tion between KD and MEFV gene mutations.
Methods: The peripheral blood of 30 patients who were diagnosed with KD based on ACC
criteria and 224 healthy people as a control group (113 male and 111 female), were collected
and the samples screened for the 12 common pathogenic variants according to manufac-
turer’s instructions.
Results: The mean age of patients (13 females and 17 males) was 7.7 years. Ten percent of
patients showed a mutation, that was meaningfully (p<0.05%) lower than that of healthy controls
(25%). E148Q was shown in two patients and compound heterozygous (E148Q-M680I) was
detected in one of them with lack of FMF presentations. No signiﬁcant and meaningful associa-
tions were detected between the MEFV gene variant alleles and KD.
Conclusion: Unlike in other types of pediatric vasculitis, this study did not reveal any
signiﬁcant association between the MEFV gene mutations and KD, moreover, because of the
lower frequency of mutations in these patients, it seems that this gene has a modiﬁer and/or
protective role in KD.
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Introduction
Kawasaki disease (KD) is an acute febrile, self-limiting, and systemic vasculitis of
unknown etiology, that occurs in infants and children, especially those in Asia
(Japan has the highest incidence), but its incidence has increased worldwide,1
perhaps due to more recognition and awareness of the disease.2 An important
genetic susceptibility to the disease is suggested by the higher incidence among
US children of Asian/Paciﬁc Islander descent in California and Hawaii (50.4 and
210 per 100,000 respectively).3,4
Though signiﬁcant differences in epidemiological features have been observed
worldwide,2 a number of factors that seem relatively constant are increased inci-
dence in people of Asian descent, a male predominance, and marked seasonality.5,6
It manifests as high fever, mucocutaneous inﬂammation and cervical lymphadeno-
pathy, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa,
changes in the extremities, and rash.3 When it was ﬁrst described, the coronary
artery complication was not recognized,2 but now the most serious late complica-
tion of KD – the involvement of coronary arteries, is known.7
Correspondence: Mehrdad Mirzarahimi
Pediatric, Pediatric Department, Bouali
Children’s Hospital, Ardabil University of
Medical Sciences (ARUMS), No 105
Azarbyjan Ave. Shahrak Azadi, 56157
Ardabil, Iran
Email m.mirzarahimi@arums.ac.ir
Open Access Rheumatology: Research and Reviews Dovepress
open access to scientiﬁc and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Open Access Rheumatology: Research and Reviews 2019:11 127–131 127
DovePress © 2019 Salehzadeh et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/OARRR.S202217
 
O
pe
n 
Ac
ce
ss
 R
he
um
at
ol
og
y:
 R
es
ea
rc
h 
an
d 
Re
vie
ws
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
37
.2
7.
13
3.
19
6 
on
 2
1-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
MEFV gene, which plays a major role in autoinﬂam-
matory disorders and innate immune reactions and is pre-
dominantly expressed in monocytes and granulocytes,8
plays major roles in the pathophysiology of KD at the
early phase.7 Several reports revealed that MEFV muta-
tions are associated with different types of systemic vas-
culitis such as Behcet’s disease, Henoch-Schonlein
purpura, and polyarteritis nodosa.9 This suggests that
MEFV gene mutations result in broader spectrum of vas-
culitis, and might increase the baseline of inﬂammation
and affect the clinical features of inﬂammatory diseases.9
To clarify the role of MEFV gene mutations in the
development of the most common type of systemic vascu-
litis in children (KD) as one of the host genetic factors and
its role in clinical preservation, courses, and prognosis of
disease, we investigated the associations between KD and
12 common MEFV gene mutations in these patients.
The role of MEFV gene in inﬂammation induced by
innate immune response may disclose the pathogenetic
background of these mutations in KD.
Materials and methods
This study included 224 healthy people as a control group
(113 males and 111 females). All of them were over 50 years
old, with negative history of FMF symptoms (including ﬁrst-
degree family). (This study was done to evaluate variants of
MEFV mutations in normal and unaffected people).
Patient group included 30 KD patients who were treated
with intravenous immunoglobulin plus oral aspirin at Bouali
Children’s Hospital from 2010 through 2018 and met the
appropriate diagnostic criteria for KD. Our study is com-
plaint with the Helsinki Declaration and was approved by the
domestic ethics committee of faculty of medicine ARUMS
(Ardabil University of Medical Sciences), approval number:
IR.ARUMS.REC.1396.254. Written informed consent was
obtained from all participants (their parents).
The principle clinical features are shown in Table 1.
Blood samples were collected from 30KD patients and the
samples were screened for the 12 common pathogenic variants
(E148Q, F479L, P369S, I692del, M680I(G/C), M680I(G/A),
M694V, V726A, A 744S, M694I, K695R, R 761H) using an
RDB assay (FMF Strip Assay, Vienna lab, Vienna, Austria)
according to manufacturer’s instructions.
Results
There were 13 girls and 17 boys; the median age at diag-
nosis was 7.7 years. The youngest patients were 1.5 years
old and the oldest one was 12.5 years old. The main
complaint from patients was fever in all of them (100%),
and fever plus changes in mucosa in 26 (86%) patients was
the second most common complaint. Table1 shows the main
symptoms of patients.
RegardingMEFV gene analysis, three male patients (10%)
showed mutations. Two patients had heterozygote E148Q and
one showed compound heterozygote E148Q-M680I (Table 2).
Control group showed 25% mutations, the most common
variants were E148Q (18.3%), P369S (3.1%), V726A
(2.2%), and A744S (1.3%), respectively.
Thirteen patients developed some degree of coronary
artery ﬁndings; brightness, dilated, and aneurysm. One
patient had compound heterozygous mutations (E148Q-
M680I), coronary artery dilatation, and micro-aneurysm.
The time between onset of symptoms and diagnosis of
KD was less than 9±2 days.
Discussion
Despite 4 decades of investigation, the etiology of KD
remains unknown. Current understanding of the immune
response suggests response to a classic antigen that is
protective against future exposure in most patients.
Expansion of the regulatory T-cell population after IVIG
administration is associated with cessation of fever and
clinical improvement. The self-limiting feature of the dis-
ease accompanied with a low rate of recurrence suggest
emergence of T- and B-cell memory cells which are pro-
tective against future encounters with the KD agent.7
Table 1 Patient ﬁndings
Clinical and para-clinical ﬁndings (N=30)
Fever = 30 (100%)
Change in mucosa = 26 (86.66%)
Palmar and plantar erythema and edema = 7 (23.33%)
Cervical adenopathy = 14 (46.66%)
Rash = 17 (56.66%)
Irritability = 9 (30%)
Coronary artery ﬁndings
(brightness/aneurysm) = 13 (43.33%)
Desquamation = 13 (43.33%)
Abdominal pain = 11 (36.66%)
Leukocytosis = 23 (76.66%)
Thrombocytosis = 11 (36.66%)
Increase in CRP = 24 (80%)
Increase in ESR = 27 (90%)
Urine analysis
Hematuria = 2 (6.6%)
Leukocyturia = 5 (16.66%)
MEFV mutations = 3 (10%)
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Although early studies provided evidence of an immune
reaction triggered by a super antigen, subsequent studies
favored a canonical response to a conventional antigen.
A study of the adaptive immune response demonstrated
that both pro-inﬂammatory and regulatory T-cells could be
found in the circulation in the ﬁrst week after fever onset.9
Activation of the innate immune system, with high num-
bers of activated, circulating neutrophils and evidence of acti-
vation of IL-1, IL-6, and TNF signaling pathways, is an early
event.7
TheMEFV gene is located on the short (p) arm of chromo-
some 16 at position 13.3”16p 13.3”.10 MEFV gene was pre-
dominantly expressed in granulocytes and monocytes,8 which
play a major role in the pathophysiology of KD at the acute
phase.2 MEFV gene encodes a protein called pyrin (or
marenostrin).11 Pyrin is involved in inﬂammation through
altered apoptosis, CASP-1 activation, secretion of IL-1β, and
activation of the NF-κB pathway in innate immune system.12
MEFV mutations' associations with different autoim-
mune and autoinﬂammatory diseases suggest its contribu-
tion to the development of a broader spectrum of vasculitis.
Furthermore,MEFVmutationsmight increase the baseline
of inﬂammation, induce the development of rheumatic dis-
eases, and affect the clinical course of inﬂammatory disorders.9
Most Japanese FMF patients showed heterozygous
mutations.13,15 Among them, E148Q was the most com-
mon mutation with a weak effect on severity of disease. It
seems to serve only to enhance FMF progression, that was
primarily induced by another mutation.14 Tunca et al
demonstrated an increased acute phase reaction in carriers
of the MEFV gene.16 Rabinovich et al demonstrated that
RA patients carrying MEFV mutations, particularly the
E148Q mutation, present with a higher RA severity score
than the non-carrier group, suggesting that MFFV muta-
tion is a modiﬁer of the clinical manifestation of RA.17
Migita et al's study in a Japanese population demonstrated
no association between the presence of MEFV mutations and
RA occurrence as well as RA-related AA amyloidosis.18
Yamaguchi et al reported that E148Q mutation was not
associated with the development of KD that occurs in a higher
frequency in Japanese children. It is possible that the func-
tional effect of this mutation might be too small to stimulate
inﬂammation for the development of vasculitis in KD.19
This study showed 10% mutations among patients with
KD, whilst these mutations among healthy control group
were 25%, where E148Q was the most frequent variant
(18.3%). This result shows meaningfully lower mutated
MEFV alleles in KD patients than healthy people. (p<0.05)Ta
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The meaningfully lower frequency of E148Q muta-
tion in these patients reveals the possible preventive and
protective role of this mutation (E148Q) in KD.
Furthermore, it seems that it could modulate the severity
and exacerbation of vasculitis in affected patients. This
hypothesis helps us to better understand Yamaguchi`s
study about the functional effect of E148Q and its
incompetent effect on inﬂammation.19 We think that in
our one patient with compound heterozygote E148Q-
M680I, who developed coronary artery dilatation and
micro-aneurysm, combination of pathologic mutation
(M680I) resulted in vasculopathy. Moreover, the high
prevalence of MEFV gene variant alleles in
Mediterranean people may explain the low rate of
occurrence of KD in this population in comparison
with Asian people.
Different patterns of geographic prevalence of KD could
have various genetic and environmental factors, and MEFV
gene variant alleles could be one of several immunogenic
factors.
Unlike in the other common types of pediatric vascu-
litis, this study did not reveal any signiﬁcant association
between MEFV mutations and KD, moreover it seems to
have a modiﬁer and/or protective role in KD.
Conclusion
This study demonstrated no association between the pre-
sence of MEFV variant alleles and KD, and emphasizes its
possible protective role in KD.
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